Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy

BACKGROUND: For advanced nonsquamous non‐small cell lung cancer (NSCLC), the mechanisms of resistance to first‐line immunotherapy are not clear. Immune checkpoint inhibitors (ICIs) in combination with agents targeting other pathways may serve as second‐line therapy options. Apatinib (a vascular endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Wang, Mengzhao, Zhao, Jun, Zhong, Wei, Chi, Yujia, Xu, Ziyi, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520805/
https://www.ncbi.nlm.nih.gov/pubmed/34409776
http://dx.doi.org/10.1111/1759-7714.14113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520805/
https://www.ncbi.nlm.nih.gov/pubmed/34409776
http://dx.doi.org/10.1111/1759-7714.14113

Ejemplares similares